Feb 22, 2014 - 4:02 pm
I am a caregiver/advocate for my mother who has stage IV, grade IV, clear cell renal cell carcinoma with rhabdoid features and necrosis. Post nephrectomy she was given sunitinib which resulted in stable disease for several months. The mets are confined to her lungs and are growing very rapidly. She was recently accepted into a clinical trial and will receive stand-alone nivolumab.
Using the search function, I found that many of you have participated in pd-1/pd-L1 trials. Would you mind sharing the grade and histological features of your tumor, and how you responded? There is some evidence suggesting that aggressive cancer cells are more likely to express PD-L1, thus increasing the chance of a response to PD-1/PD-L1 drugs. It would be interesting to see if such a pattern holds true to the small cohort of this forum. Perhaps it can give those with poor prognosis some hope.